Following the recent withdrawal of Sorbsan we would like to draw your attention to CovaWound™ Alginate as a possible alternative.
CovaWound™ Alginate is made from the calcium salt of alginic acid (rich in mannuronic acid) and displays natural haemostatic properties to facilitate wound healing. Like Sorbsan, CovaWound™ Alginate is indicated for moderate to heavily exuding wounds and available as a flat pad, rope or ribbon.*
In tests undertaken at The Surgical Materials Testing Laboratory (SMTL) CovaWound™ Alginate was found to have both high absorbency and retention capabilities. CovaWound™ Alginate is also shown to have excellent tensile strength when wet, which means that the dressing maintains integrity to facilitate intact, gentle, dressing removal whilst minimising the risk of residual residues in the wound bed.
Effective performance has been further demonstrated in a recently published case series evaluating the use of CovaWound™ Alginate in patients with moderate to highly exuding lower limb wounds.
CovaWound™ Alginate is also priced competitively and is currently ranked first on price through the NHS Supply Chain Advanced Wound Care Framework, which means that by switching to CovaWound™ Alginate, clinics also have the opportunity to make savings on their wound dressing spend.**
For further information on CovaWound™ Alginate we have put together an FAQ information piece in response to numerous recent enquiries. Additionally, the SMTL data and cases series study referred to in this article are available within the resources section of our website.
We welcome you to get in touch and request a product sample to evaluate the dressing for yourself. For further information or to request a product sample please contact us today at
*References cited in ‘Alginate FAQs’ found within the resources section of our website.
**Drug Tariff published pricing, December 2019.
Covalon Technologies (Europe) Ltd, No 1 Mill, The Wharf, Shardlow, Derbyshire, DE72 2GH
T: +44 (0) 1332 322469